Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Diamond Biotechnology Co's Revenue for the
six
months ended in Dec. 2025 was NT$183.9 Mil. Diamond Biotechnology Co's average Accounts Receivable for the
six
months ended in Dec. 2025 was NT$151.5 Mil.
Hence, Diamond Biotechnology Co's Receivables Turnover for the
six
months ended in Dec. 2025 was 1.21.
Diamond Biotechnology Co (ROCO:6815) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Diamond Biotechnology Co Receivables Turnover Related Terms
Diamond Biotechnology Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Diamond Biotechnology Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biotechnology Co Receivables Turnover Chart
ROCO:6815 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Diamond Biotechnology Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamond Biotechnology Co Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Diamond Biotechnology Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Diamond Biotechnology Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biotechnology Co (ROCO:6815) has a Receivables Turnover of 1.21 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Diamond Biotechnology Co and its competitors. According to the industry distribution chart, Diamond Biotechnology Co ranks #704 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 86.6%.
Is Diamond Biotechnology Co's Receivables Turnover too high?
Diamond Biotechnology Co's current Receivables Turnover is 1.21. The Medical Devices & Instruments industry median Receivables Turnover is 5.60. Diamond Biotechnology Co's value of 1.21 is 78.4% below this industry median. Based on the distribution chart, Diamond Biotechnology Co ranks #704 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Diamond Biotechnology Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamond Biotechnology Co's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Diamond Biotechnology Co ranks #704 out of 813 companies for Receivables Turnover. This places Diamond Biotechnology Co in the lower half of its industry. The industry median Receivables Turnover is 5.60. Diamond Biotechnology Co's value of 1.21 is 78.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.60, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamond Biotechnology Co's current Receivables Turnover of 1.21 is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Diamond Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biotechnology Co's current Receivables Turnover is 1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Diamond Biotechnology Co (ROCO:6815) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.19, compared to a current price of NT$24.95 — trading 48.2% below its estimated fair value. The current Receivables Turnover is 1.21 and 78.4% below the Medical Devices & Instruments industry median of 5.60. Diamond Biotechnology Co's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Diamond Biotechnology Co (ROCO:6815), the current Receivables Turnover is 1.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamond Biotechnology Co (ROCO:6815) Overvalued in 2026?
Based on GuruFocus' analysis, Diamond Biotechnology Co stock appears to be undervalued.
The current stock price of NT$24.95 is trading 48.2% below its estimated GF Value™ of NT$48.19.
GuruFocus considers Diamond Biotechnology Co to be Possible Value Trap.
Key valuation signals for ROCO:6815:
Receivables Turnover: 1.21
GF Value™: NT$48.19 vs. price of NT$24.95 (48.2% below fair value)
Industry Position: 78.4% below the Medical Devices & Instruments median (#704 of 813)
No single metric tells the full story. See the ROCO:6815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.
75GF Score
Get the complete analysis for ROCO:6815
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6815 has been successfully added to your 
